Last reviewed · How we verify
Ribavirin plus Xiao'er jiebiao oral liquid
Ribavirin plus Xiao'er jiebiao oral liquid, developed by the Children's Hospital of Fudan University, is a marketed combination therapy. The key composition patent expires in 2028, providing a period of exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | Ribavirin plus Xiao'er jiebiao oral liquid |
|---|---|
| Sponsor | Children's Hospital of Fudan University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: